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1,25-Dihydroxyvitamin D 3 [1,25(OHhD31 transacti-
vates its target genes via the vitamin D receptor 
(VDR). VDR functions in physiology as a dimer 
complexed with retinoid X receptor (RXR), whose 
natural ligand is 9-cis-retinoic acid (9-c-RA). Inacti-
vation of 1,25(OH}zD3 occurs through a cytochrome 
P-450 24-hydroxylase (OHase). The promoter of the 
human 24-0Hase gene contains a 1,25(OH)2D 3-re-
sponsive enhancer element (VDRE). We have used 
this VDRE containing gene as an endogenous re-
porter for vitamin D 3-mediated gene activation ;11 
vivo. Normal adult human skin was keratomed after a 
2-d exposure to 1,25(OHhD3' 9-c-RA, all-tl'a1ls-RA, 
and ketoconazole. 1,25(OH}zD3 caused a concentra-
tion-dependent increase in 24-0Hase mRNA expres-
sion as determined by northern blot analysis. The 
activity of epidermal 24-0Hase was also induced 
by 1,25(OH}zD3. Compared with vehicle, neither of 
t he RA isonlers nor ketoconazole alone induced 24-
OHase mRNA. Addition of 9-c-RA or t-RA to 
1 ,2 5-0ihydroxyvitamin D J [1, 25(OHh 0 31 is a bioa ctive hormo ne c ritical in seven11 cellular and ph ys io logic processes . In addi tion to its well-established importance in plasma calcium ho meostasis (Doyle et al. 1972; Holick et ai, 1972). 1.25 (O H) 20 3 also affects ce ll prolifera tio n 
a nd di ffe rentia tion (Colston CI ai , 1981; T an aka et ai, 1982; Smith el 
ai, 198 6) , as w e ll as T-cell acti vation (Mlille r and Bendtzen , 1992 ; 
B agor et ai, 1994). Th e seemingly dive rse e ffects of 1.25 (O H)20 3 
are m ainly m ediated thro ugh its intrace llular vitamin 0 recepto r 
(VDR) . VDR is a member of the ste ro id / re tinoic ac idlthyro id 
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1,25(OH}zD3' however, caused a synergistic increase 
in 24-0Hase mRNA. Similarly, 1,25(OH)2D3 plus 
ketoconazole increased 24-0Hase mRNA synergisti-
cally. Ket oconazole inhibited ex vil10 1,25(OH}zD3-
induced epidermal 24-0Hase activity. Thus, 24-
OHase mRNA induction is a sensitive reporter of 
1,25(OH}zD3 activity ill vivo; RXR bound to VDR is 
not a silent partner ill vivo, because 9-c-RA enhances 
1,25(OHhDrliganded RXRJVDR stimulation of the 
VDRE containing 24-0Hase gene; ketoconazole in-
hibition of 24-0Hase enhances 1,25(OH}zD3 activity 
by impeding its breakdown. Thus, the synergistic 
response of human skin to topical 1,25(OH}zD3 and/or 
1,25(OHhD3 analogs plus RXR retinoids and/or ke-
toconazole may be exploited to give a desired biolog-
ic/therapeutic response with less 1,25(OH}zD3, mini-
nlizing the potential calcemic risk from systemic 
absorption of 1,25(OH}zD3' KCJI words: meta.bolistll. 
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hormone nu clear rccepto r supel'family. As such , it fun cti ons as a 
ligand (ho rmon e)-dependcllt transcriptio n f.1c to r, regulating the 
activatio n o f v itamin O-responsive targe t genes . U nlike stero id 
receptors th at fun ction as hom odimers, the V OR appears to 
fun ction predominantl y as a he te rodimcr (Lem o n and Freedman, 
1996). T he he terodimeric parmer o f VDR is re tinoid X recep to r 
(RXl~) whosc natural ligand is 9-cis-re tino ic acid (9- c-RA) (Hey-
1113n et ai, 1992 ; Levin 1'1 ai, 1992) . In addition to VD R , RXR 
hetcrodimerizes w ith o ther nuclear reccpto rs includin g, but not 
limited to . re tinoi c acid receptors (RARs) and thyroid horm on e 
receptors. 
M ost of o ur current understanding o f the m o lecular m echanism 
b y which VDR activates its ta rget gcn es h as b een through studies in 
;f( 1I;lro system s o r in artifi cia l ceU-transfec tion m od els. T he inheren t 
limitations o f these ;f( ,,;fro system s to predic t ;f( 11 ;110 situations, 
especiall y with regard to the ro le o fRXR and its li gand in vitamin 
D signalin g, arc clearl y dem onstra ted by inconsistent findin gs 
(M acD on ald cl ai, 1993; Sasaki cl ai , 1995; Kan e cl ai, 1996) , w h.ich 
undcrsco re the necessity to directl y in ves ti ga te th e ;f( /1 ;/10 sys tem o f 
inte rest. Skin is clearly a targe t o rga n fo r 1 ,25 (O H hO,1 with its cells 
constitutive ly expressing VDRs (Berger ef ai, 1988; Milde et ai, 
1991). Furtherm ore, certain di seases. such as ichthyosis and psori-
asis. respo nd to 1,2 5(O H) l D, and its re lated compounds (Krag-
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bal le, 1<)92) . Pri Ol' to o ur s tud y, h o w e ve r , th e re had been a lac k of 
sp ecifi c m e asurable 1l1arke rs of vitamin D ac tivi ty in human skin ill 
I'iIJ() . This d e fi c ie n cy has limi te d the study o f the e ffects and 
m o lecular si g nalin g o f th ese m o lecules in human sk in ;11 1';1'0. 
24-H ydro'-'Ylase (O Ha se) is a cytochro m e P-4 50 e n z yl1l e tha t 
hydro x ylates 1 ,2 S(O H h D J at: the 24 p osition, resultin g in a m e -
tabo li te . 1.24. 25-trih ydrox yvitilmin D:\ 1.1.24 ,2 S(O H)}D }J. with a 
m arke dl y re duced ac ti v ity (H o li ck ('/ ,Ii. J 9 73; O h yama and Okuda , 
1( 91) . R,ecent c lonin g o f thi s gene hil S reveal e d tha t its natural 
pro m o te r harbo rs vitamin D resp o n sive e le m ents (YD IU ) that are 
composed o f AGGTCA- like hexameric direc t re p eats separate d b y 
3-bp-a so calJ e d DR3 (Oh yam a el ai, 1994; Zierold cl ai , 1995) . 
Thi s type (DR3) of e nhan ce r c le m e nt ha s a lso b een identifi ed in 
o ste o ca lcin and calbindin D~K gen es (Ke rn e r £'1 ai , 1989; D arwish 
and D eLu ca, 1992) '\I1d appe ars to be the ph ys iol ogic ally relevant 
YDRE. A lth ou g h some reports of VDR- YDR h o modil1'1 e rs bind-
in g to VDR.E ex ist (C arlbe rg 1'1 (/1 , 1993 ), prevailing evide n ce p o ints 
to R X R - VDR h e tero dim e r as th e majo r comple x tha t binds to the 
YDR E (Yu 1'1 ill. 199 1; Ke phart 1'( (fl , 19 96). In deed. e ndogen o u s 
VDn .. in nucl e ar extra c ts fro m hum an epide rmis and culture d 
human ke ratin ocytes binds to its recognition si te (DR3) as a 
h e te ro dime r (RX H .. -VDR) and not as a homodim e r (YDR-VDR) 
(Li {'( (fl , 1(97) . In c ultured human k e ra t in ocytes, 'I ,2S(OH h D , has 
b een reported to e nh an ce the express ion of 24- 0 Hase mRNA 
(C h e n ('( aI, 1994). In thi s study . w e in vesti gated the regulation o f 
the 2 4-0 J-lase g en e , which contain s a natural VDrU in its pro -
mote r . in human sk in ill 11;1'''. I-lerein w e repo rt that the 9 -c-RA, 
li gand o fRXR . syn e rgisti ca ll y e nhances the abi li ty of J .25 (O l-I) , I) , 
to indu ce 2 4-0Hase ge n e tran scrip ts, and furth e rmo re, a sin;ila;' 
response ca n b e ac hi e ved by inhibiting the ina c tivatio n o f 
1.25 (O H h D \ b y li se o f a 24 - 0 Hase inhibitor. 
MATErtlALS AND MET I-I O DS 
Materials 1.25 (0 I-l >O D ,. 25-h ydroxyvital11in D , or cho lecalcifero l 125-
0 1-1])" , 24.25-dih ydroxyvitamin D , [24.25(01-l), D, I. 25.26-dih ydro xy-
vita l11in Dol r25 .2() (0 1-l) 2D, I. 1,24,25(0 I-l h l), . 1,25 .26-trih )'drox ),v italll in 
DJ 11.25.2('(0 1-l).,DJ I. and 9-(- I ~A were gifts (i'om Dr. Milan rt. Uskokovic 
and Dr. Pete r Bo lI"g at I-I o ffmann La R oche (Nutley. NJ). AII - lm1lS-reti ll oic 
acid (I-R A) was purchased frol1l Sigma (S t. LOlli s. MO ). Ketoconazo le 
powder wa.' a gift fi'om Dr. Gcc rt Cau wcnbergh at J ohnson and J ohnson 
(S killlll an. NJ ) and Dr. Allnie I-I erelllans atJ 'lII ssen I'ha,.,lIa ceuti c,,! (Beerse. 
Belgilll1l ). Deoxycytidinc 5'-1 a-.. 12 Pltriphosplw tc and 25-I ' I-IJ O I-ID., (25-
0 1-l1 26.27-lII clli yl- Jl-ll cho leca lciferol) were purchased li'o lll DuPo ll t-N EN 
(Bos ton. MA) and Allle rshalll Life Science (Arlington I-I eights. IL) . respec-
ti vel),. 
T reatment of Subjects and Procurement of Tissue Solu tions of 
1.25 (0 1-1 )21), (O.()(l04 'YO •. 1I .lliI2%. 0.0 I %. and 0. 05%) . 9-(-rtA (0 .1 %). I-RA 
(1) . 1 'Yo,). kc toconazo le ('I %). 1.25(0 I-l )o DJ pillS 9-c- I ~A (0 .002% and ll.'l %. 
respec ti ve ly), 1.25(O I-l ), D, plus I- I ~A (O. O() 2% and 0 .1 %. respec ti ve ly). alld 
1.25(01-I),Dol pillS ke toconazo le (O. 002'Yo, and 1%. respeCli ve ly) we re 
prepared in a vc hicl e consistillg o f 95% e thanol alld pro pylelle glyco l, 7:3 
(vo l /vo l). Each solution also cOlltained the all ti-ox idant hlltylatl'd hydroxy-
to lulcne (0 .5 IIl g pe r 1111 ). O lle hundred micro li ters of the stll dy so lutio", 
were applied once to arcas 3 CI11 X 6 CI11 on buttoc k skin o f no rl1\al heal thy 
adu lts. Sites weI''' occlnded with Sa ran wrap and then covered with a 
tape-secllred light- proof dress ing fo r 2 d . For treatl11ent wi th ketoconazo le 
plus 1.25(0 1-l), D,I ' the stlld y sites were treated wjth the il1\idazo le for 3 h 
befo re application o f the cOl1lbina tion so lution. Treated areas were infil-
t rOl ted wi th I tXt li d oc:l ill c local an es th es ia al1d biopsic d w irh a kcrfl to ll1 c 
(= 150 Jl.nl thi ck). J{ c ra tO l11 ed specil1l ens were iml1l edia tely fi'oze /1 in liqllid 
nitrogt' n '\/ld sto red at - 700 IIn tilll sed . All subjec ts gave info rm ed written 
CQ I1$cnt" ill a pro toco l th .n had rece ived pr ior approva l by th e Ulli vers ity o f 
Michigan Medica l Center Institurio lwl R evie w Board . 
Measurement of 24-0Hase mRNA For ll1l!asure l11 en t o r 24-0 1-lase 
nrl~NA . to tal ce lllllar RNA was ex tracted fro m keratol11 e bi opsies o btained 
ilS dc'\crihcd :l bovc. The g ua nidiniull1 iso thi o na tc-ccs iul11 chl o ri de proce-
dure was used as desc ribed (Elder ('I al. 1990). RNA spec ics (20 Jl.g pe l' 
" 'n'plc) were clec tropho re ti call y size- fi 'acriona ted on agarose ge ls and 
transfe rred to d c ri vati zed n ylo l1 111Cfllh r :lll cs . The blots we re seque ntia ll y 
hybridized aga inst .12 1'- labeled 24-0 1-lase cD NA and 3G B4 (Astrol1l ci nl. 
199 1). DNA pro bes were prepared by rando l11l,,;ming (Bochringe r Mann-
l1 e il11 . Indian apo lis. IN) and quanti ta ted by using a Phosphor lmager (Mo-
lec lli ar Dynamics. Sllllll )'va le . CAl as descrihed (Elder ('1 al. 1990; Astro rn ('I 
T H E JOU R NAL O F INVESTIGATIVE DERMATOLOGY 9 
nl. 19') I). e"('''p t that 36 B4 rather than cyclophilin was nsed as the contro l 
pro be. In tegrated auto radiographic intensity o btained by Phosphorlll1ager 
lo r the 24-01-/ase gene was lirst di vided by that o f the control gelle (3 6B4). 
Th e divi sio n produc t" was th en di vided ag ain b y t'h ~l t o f the contro l tre~ltlll e llt 
for relative cOl11pa risons. Beca use the nC[;ative ('ontro l (vehicle) group 
con tained man y sl11all nU111bers, including zero. which precillded the 
require d CO lllptltati o n s (di visio n b y zero), data arc e xpressed as pe rcen t 
inducti on o f thc positive contro l (1).05% I ,25 (0 1-l),D, ). which was consid-
e red Inax il1lll1ll induc t-jo n . 
Measurement of 24-0Hase Enzytne Ac tivity HUl11an skin trca red 
with vehiclc and 0 .05% 1.25(0 1-l),D , lor 2 d under continuo us occiusiolJ 
w as kcrato nlc-biopsicd . T he biopsy specinlCl1s w e re incubated in trypsin 
(0 .1 % in solution consisting o f 30 mM I-IE PES buffer, 10 111M glucose. 3 mM 
KC I. 130 111M NaC I. and I 111M sodium phosphate. 1'1-1 7,2) ('or 30 min at 
35°C to separa te thl' epidermis &om the dennis. Dispersed epidermal cell s 
were centrifuged at 2000 X .~ lo r 5 l11in . Thc pe ll eted ce ll s were resuspcnded 
in 5 ~111 o f 0. 1 % trypsin inhibitor and then cen trifuged again at 2000 X g fo r 
5 111n1. T he cells wc re washed twice with 5 ml of the diges ti on buffer 
(wi tho ut trypsin). T he fin al ce ll pe ll et was resuspended in I 1111 of cnzyl11 e 
assay bull'c r (20 111M I-I Ei'ES bull'c r. 125 111M KC I. 2U u,M succ inate . 2 mM 
MgCI" I 111M di thio threito l. and 1 111M eth ylenediamine terraacetic acid. 
pH 7.4 ). To 2U Jl.1 o{'resuspended ce ll s. I I.tM 25-1 ·' 1-1.1 0 I-I D.I ( I Jl.Ci) was 
added to s,.art the reacti on. When lI sed . ke toconazo le was added at a fi nal 
concentration of I X 10- " M. After a 30- l11in incuba tion at 35°C, the 
react'ion was stopped with rhe addition of 2.6 Inl of l11ethano l:chl oroform . 
2: 1 (vol /vo l). After adding 1.2 ml of chlo roforl11 and I 1111 o f water, the 
s;ll11plcs w ere vort'cx-lllixcd fo r 'I lniJl alld thell allowed to se parate i_llto two 
layers. Thc aqueous laye r was was hed twice with 1.2 1111 0 (' chl oroform . 
W ith each wash. the chlorofo rm la ye r was pooled and then evaporated to 
dryness . and the nlaterial was res lI spended in 200 Jl.1 of l11 e,.hanol. The 
rnaterial was fi lrered with Millipore SJI-IV 004 filt ers into high-performance 
liqnid chro/l)atogr;'phy vi,ds. Afte r eva po ra tion to dr)'ncss the material ,,,as 
taken lip in a I'inal vo lum e of 3(1 1.1,1 f.o r high- perto nnal1ce liquid chroma-
tograph y al1al ys is. 
High-Perforrrtance Liquid Chromatography Separation of Vita-
min 0 , Metabolites The stnlldard used to idc lltif), al1d quanti tate 
vitamin D., metabo lites were 25-0 1-11)" 24.25(0 I-l h l),. 1,25 (O Hh D3' 
25.26(O H), I),. 1.24.25 (O I-l) .,D,I' and 1. 25.26 (0 1-1) ., )).1' Vitamin D, me-
ta holi tes wcre separated by using a Hewlett-Packard I090M high-pcrfo r-
IlJaIl CC liquid c hrolllatograph y sysr C llt w ith a c he rn wo rk sta t. io n . :l pilo t 
wavelength of 264 nm , and a Sphcri so rb o n S I co lumn of 4 .6 X 200 nll11 . 
An isoc ratic elution with ')0% solvent A (acetonitril e) and 10% solvent B 
10 .0(15 M anll11o l1ill1n ace tate :a ce ri<: acid . 100: I (vo l/vo l),1 was achieved 
with a fl ow rate of U. 7 ml l l1,il1 at 26°C fo r 22 min . The elHlIent fi'om thc 
co lul11n Ilowed direc tl y il1 to a Radi ol11 ,lti c l11 0del 295A now thro ugh liquid 
sci ntiUa tio ll spcc tro lll c tc r fo r quallfi tati o n of tr iti uI11 in eac h o f th e separated 
r1 lCtBho lircs . 
Statistical Analysis Comparisons o f mean levels of 24 -0 1-l ase m ftNA 
a/\long treated sites were l11ade with e ither the paired I' tes t o r the repeated 
ItlC:lSUrCS ana lysis o f vari:lll c t~ . All p values arc rw o-s ided. SUllullary statisrics 
arc expressed as Ill COln s ± SEM . Da ta anal ysis w as pc rfo rlllcd w ith dlC use 
of the Michigan Inte ractive Data Allalysis Sys tem (M IDAS). a sta tistical 
softw are pack~gc developed at the Cel1ter to r Statisti cal Consulta tion and 
I ~esearc h at the Un ive rsity o f Michigan . 
RESULTS 
24-0Ha5e Gene Expression Is Induced by 1,25(OH)2D3 in 
Human Skin To dete rmine whether the 24-0Hase gene in 
humnn skin can he regul a te d ;11 l'iI,,, b y 1 ,25 (OH h D J • four diiferent 
con centration s o f th e hormone were applied once unde r o cclusion 
fo r 48 h . Northe rn blo t anal ysis re veale d a con centra tio n-depen-
dent induction of the 24-0Hase m[~A le ve ls (Fig 1). [n vehicle-
trea ted skin . the ml~A level wa s very low and often undetec tabl e. 
Fo r thi s reason , the data are expressed as fi'ac cions o f the level 
o bserved with O.05'X, 1 ,25 (01-1)" 1),, the hi g hest con centration 
u sed. arbi traril y set at 1 00% (max imum induc tio n). As compared 
with ve hi c le trea tm e nt. the app li cation o f 0.00 2% I ,25 (OH) 2DJ 
caused a small hut stati sti call y sig nifi cant inc re ase in the mRN A 
le ve l (p < (l.0 5 ; n = 5). 
24-0Hase Gene Expression by 1,25(OHhD3 Is Synergisti-
cally Induced by 9-c-RA Afte r d e te rmining th e dose-respo nse 
c urve fo r 24-01-):l se mRNA in du ction by 1.2S(O H h D , applica-
tio n , w e in vestig ate d wh e th e r the slll a ll in c rease in 24-0Hase 
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Figure 1. Northern blot: analysis of24-0Hase gene expression after 
a 2-d occlusive 1,25(OH)2D, treatment. Norllla lized 24-0 Hase IllRN A 
levels were dcrcrlll iJl cci as ciescrib"ci ill Jlinl!'ri"I.< ,'lId illelhods. Em'r hnrs, SEM 
(n = 5). ' 1' < 0.05 I"TSIIS v"hick (OpCIl b,,,·). Vir D., . 1.2S(O Hb D.I (solid 
bars). ( 1IIs!'I) Il...esults Ii'o lll two represenrativc subjec ts. 
mRNA caused by a low dose of 1.2S(0 1-l),D3 (O .002 'X,) co uld be 
augmented by the applica tion of 9-c-RA. Co mpared w ith vehicle, 
9-c-RA by itself did not change hum a" e pidermal 24-0Hase genc 
express ion after 48 h of occlus ive trcatme n t (Fig 2). Similar [0 that 
shown in Fig 1. 0.002'% 1,2S(0 1-l)2D , alone induced a small but 
signitlcant increase in 24-01-l<l5C ml~NA level (18% of maximum; 
p < 0.05 versus ve hicle, n = 15). Whe n 0 .002% 1,2S(OHhD J' 
however, was co-ad m iniste red with 0.1 % 9 -(- 1~. the combinatio n 
ca used a synergistic increase ill ml~NA level [0 33% of maximum 
(p < 0 .05 ve rsus 0.002% 1,2S (O)-/)2DJ; n = 15). 
24-0Hase Gene Expression by 1,25(OHhDJ Is Synergisti-
cally Induced b y t-RA W e ha ve demonstrated th at after [Opica l 
application of I-RA [0 human ski n. its stereoisomers including 
9-c-RA can he de tected in thc viable e pidermis (Duell CI III, 1996). 
Therefore , wc n ext so ught [0 de termine w hether concom itant 
treatment o f 1,2S(0I-lhDJ w ith I-I~ can enhancc indu ctio n of 
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F igure 2. 24-0Hasc gene expression in hUluan skin ;11 P;II() is 
increased synergistically by 1,25(OHhD, and 9-c-RA. Normalized 
24-0Hase mll...NA Icvels were detenllilled as described ill !\I(I(crinls (1/111 
Melhods. Error "ors, SEM (n = IS) . *1' < 0.05 /IS (I.002'X. 1.25 (0I-lh D, : t p < 
0.05 vcrsus vehicle (opell bar). )) .1 ' 1. 25(01-1} ~)).1 (hatched bars). For 
0.002% D, plus 0. 1% 'J -r- ll...A (so lid bars) treatlllen .. , tbe bar height is ta ller 
than the addition of heights caused by trciltl\lent of each age lll alollc by the 
top (stippled) segment (= synergisl\l). (Ill sel) Il...esults from two rcpresellla-
rive subjects. 
Qj~ 
ili O 
...J ~ 
<tLO 
zC! 
er .... 
E 0 
-
(1) c: 
> (1) 
:;:~ 
.!!!(1) 
(1) a.. 
er~ 
VITAM IN 1) SICNA LING IN II U MA N SK IN 1,\ ' 1'/1"0 515 
100 l-
50 
40 
30 
20 
10 
0 
<t co: 
a; a: 
24·0Hase 
.......... 3684 
Subject 1 Subject 2 
Vehicle .002% 
03 
.1% 
tRA 
.002% 03 
+.1%t RA 
t 
.05% 
03 
Figure 3. 24-0Hasc gen e expression in hUlnan skin ;11 "i"o is 
increased synergistically by t ,25(OHhD, and I-RA. Norll\aE:wd 
24-0 1-13 SC I\lIl...NA levels were dcterl1l illl:ci as described ill A/f/IC'ri"ls mill 
1\I(,II",ds. Em)r linn. EM (n = 15). ' 1' < O.lIS )'s 0.O()2'X, 1. 2S(O Hh D, : t l' < 
O.US I"TSII5 vchicle (ope ll bars). I),. 1.25(0 1-1),1).\ (harched bars) . For 
0.002'X, D3 plu s n.1 % 1-1l...A (soLid bars) treatl\lellt. the bar heighr is railer 
thall the additiOIl of heights caused by trca tlll cnr of each agc llt alolle by the 
top (stippled bar) segment (= syncrgisl\l). (IlIscI) R.csults frol\l tWO rcprc-
sC IHariv c subj\!cts. 
24-0I-lase I11I~NA . similar to that o b served with 9- (-RA co-
appli cation. Two days o f occl usive treatm cnt w ith I-RA alo n e did 
no t indu ce 24-0Hase I11I~A express io n . as compared with vehi c le 
(Fig 3). Compared to (1.05% 1,2 S(0I-l) 2D , (m aximum induction). 
O.002°j" 1.2S(OH)2D , enhanced th e express ion of 24-0I'bse 
mRNA by 28% (p < o.ns [/e rSIIS veh icle, n = 15). In the presence 
of 0 .-1 'x. I-RA , howevcr, 0.002% 1. 2S(0I-l h D , treatment sign ifi-
cantl y indu ced the mR.NA le vel to m o re than 40'X, of the level 
observed w ith O.OS'1., 1.25(0I-lhD.l (p < O.OS /lcrs I I,\" 0.002% 
1.2S (01-l) 20 .\ . n = I S). 
24-0Hase Gene Expression by t , 25(OH)2D 3 Is Significantly 
Enhanced by Ketoconazole Ke toconazole is an im idazole 
k.Jlown to inhibit severa l 1>-4 50 e nzym es invo lved in ho rmo nc 
m eta bo lism. It also possesscs an inhibi to ry ac rivity against re ti no ic 
ac id 4-0Hase . wh ich in ac tivates I-RA (Duell 1'1 ai, 1992). We ha ve 
reccntly de m o n strated that inhibi t ion of 4-01-lase b y liarozole. a 
related imidazole, a ugments hUl1lan skin respo nses to low doses of 
rctin o ic acid and retin o l (Kang CI ([I . 1996). To dctermin e whcthcr 
kctocona zo le can simila rl y influ e nce vitam in D sig na ling in human 
skin by inhibitin g the 24-0Hase, we examined th e induc tio n of 
24-01-l"se mRNA by 1 ,2 S(01-lhD, in the prese nce and abscn ce of 
the imidazole. Consistcnt with previo us experiments. O.ll02% 
1.2S(0 I-l hDJ alone caused a sma ll but sig nifi can t in crease in the 
24-01-lase mRNA level as compa red with ve hicle ( 18% of llIaxi-
mUIll ; p < O.OS) (Fi g 4). Ketoco nazo le at I % alo ne did no t alter the 
ml~A level. Ketocona zole w hcn combined with 0.002';1" 
1,2S(0 1-l)2D ,. ho w ever. s),u c rg istica ll y inc reased the tran script 
leve l to approxim ately h alf of the maximal indu ctio n caused by 
0.05'1., 1,2S (OH hD, (Fig 4; p < 1).05 . n = 15). 
1,25(OH),D3 Induces I-Iu111an Epidermal 24- 0Hase Activity 
a nd Ketoconazole Inhibits the Induced Hydroxylase Activ-
ity To determin e wh ether ketoco nazo le C'ln ind ecd inhihit 24-
O I-Iase en zyme activity . we first studied the indu c ibility of thc 
cytochrome P-4S0 e nzyme activity in hUl1lan skin ;11 1';1''' by O.OS% 
1.2S (OHhD3 occl usivc treatmcn t for 2 d. Epidermal ccll s derived 
fro m vehicle- and 1.2S (OH h D , -treated sites were assaycd tor 
transform ation of 2S-0HD, to 24,2S(O H) 2D , . Compared to ve-
hicle (25 ::!:: 15 pg pe r min per I11 g of protein). the re was a I O-told 
inc rease (p (l.OS; n = 5) in the fo rmation of 2.J., 2S (01-lh D , by 
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Figure 4_ 24-0Hase gene expression in human skin ;11 11;"0 by 
1,25(OH)2D3 is increased synergistically with ketocollazole_ Nor-
malized 24-0 1-lase mRN A levels were determined as described in Malaia/s 
a",1 Melhods. E n'Ol' hal'S, SEM (n = .15). "p < 0.05 "s 0.002')lu 1.25(OH),03; 
'fP < 0.05 "CI'SIIS vehicle (open bars). 0 3' 1,25 (01-1)20 3 (hatched bars); 
Keto. ketoconazole (so lid bars) . For (l.002% 0 3 plus 1 % ketoconazole 
treatment. the bar height is taller than the addition of heights caused by 
treatment of each agent alone by the top (stippled bar) segment 
(= synergism). (fll sel) Resul ts fi'om two representative subjects. 
1,2s(OH)2D3 (260 ± 78 pg per min per mg of protein) (Fig 5). 
T his induced activity of24-0 H ase by 1,25(OH)2D 3 treatment was 
completely inhibited by addition ofketoconazo le (1. X 10- " M) ex 
lIillo (Fig 5). 
DISCUSSION 
This study demonstrates th at 24-0Hase gen e expression in human 
epiderm is is increased ;11 Il illO by topica l app lication of 
t,2s(OH)2D 3' Furtherm ore, tlus stimu lation is furthe r in creased 
synergisticaLly by the presence of an RXR Li ga nd or a 24-0Hase 
inhibitor. 
Vehicle 
.05% 03 
o 
,.. 
,.. 
50 100 150 200 250 300 350 
24,25 (OHh 03 Formation 
pglminlmg Protein 
F ig ure 5. 1,25(OH)2D3 stimulates 24-0Hase activity and kctocon-
azoIc inhibits the stimulated 24-0Hase activity. Condi tions for ;11 
"ilm assay of epiderm al ceUs derived [rom vehicle- and 1.25(01-1)20 , -
treated sites and ana lytical procedures are deta iled in Materials am/ Melh"ds. 
Emil' /,,//'s, SEM (11 = 5). ' 1' < 0.05 1'5 0.05% 1 ,25(0 1-l),D, without 
kctoconazole. 0 3' 1.25(0 1-1),0, . Opell ba.r, vehicle trcatment; hatched bar. 
1,25(0 1-1),0 , treatment; solid bar. 1.25(0 1-1),0, treatment plus ketocon-
azoic (I X 10- 4 M). 
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T he concentration-dependent induction of 24-0 Hase mRN A 
express ion by 1 ,2s(OH)2D , indi cates th at in human skin ;11 lI illO, th e 
presence of on ly the VDR ligand is suffi c ient to activate the gene . 
T he bare ly detectable 24- 0 Hase mRNA levels in no mlal (vehicle-
treated) skin and the J'Obust induction of tlus gene transcl;pt by 
1,2s (OHhD) ma ke this a potentially useful bioassay to test for 
vitamin 0 activity of a compound in human Skill ;11 /1;110. T his 
appears analogous to ce llular retino ic acid binding protein 
(CRABP)-II mRNA induction by topica l retin o id in hum an skin. 
Enhanced expression of thi s gene, w hose far upstream promoter 
contains a retinoic acid-responsive e le ment (Astrom CI (//. 1991), by 
an occlusive treatmen t w ith natural Or synthetic retino ids has 
predicted their retin o idal activ ity in human skin ;11 /1 ;110 (Grifriths CI 
(//, 1993; Elder ci (/ / , t 995). T he potential va lue of 24-0Hase gene 
expressio n as a measure of vitam in D activi ty in human skin, 
however, would be greater than C RABP- II mIlNA induction for 
retino ids. T his is because, although retinoids typica ll y give dose-
dependent responses clinica lly (i.e., erythema) and/or histologically 
(i.e., hyperplasia of the epidermi s), 1,25 (OH)2D) and its synthetic 
anal og calcipotl'i ene, which is cun'entl y in clinical usc, do neither 
(Kang and Voorhees, unpublished data; Kragba ll e, personal com-
muni cation). T hus, inductio n of 24- 0Hase mRNA provides a 
detectable 1,2s (OH)2D 3 target in the absence of any appreciable 
clinical or histologic activity in human ski n ;11 I' ; IJO. Furthermore, 
this enh anced express ion of 24-0Hase mRNA by 1,25(OHhD3 
treatment corre la tes w ith an in crease in 24-0 Hase enzyme activi ty. 
T he abiJi ty of 9-c-RA to synerg is tica ll y enh ance the 24-0 Hase 
mRNA level induced by a low dose of 1 ,2s(OH hD) indicates that 
RXR is not a sil ent partner in RXR-VDR heterodimer complex-
m ed iated vitam in D sign alin g in human skin ;11 V;'1(' . T his ;11 lI;'m 
finding is consistent w ith our ;11 1';lm data. In cell culture, human 
ke ratinocytes from norma l adults transfected with a reporter gene 
V D R E (DR.3)-lk-CAT (w here CAT is chlo ramphemicol acetyl-
tran sfe rase) dem o nstrated m ore than a doubling of chl o rampheni-
col acetyl transferase activity when 9-c-RA was added to a low dose 
of 1 ,2s (OH)2D3 (Li cl ai, t 997). T hi s chl oramph enicol acetyl trans-
fe rase activity co uld be further in creased by overexpressing VDR 
and / or RXR in the transfected keratinocytes, wluch strongly 
i.ndi cates the direct con tri bu tio n of the receptors to the ligand-
media ted in ducib ility. 
Although 9-c-RA is th e o nl y n aturalliga lld ofRXR identified to 
date, it is a lso an agonist of l'lARs (Heyman cl ai , 1992; Allenby el 
(//, 1993). In add ition, beca use 9-c-RA can isomerize to I-RA in 
human sk in tissue (Duell cl (//, 1996), a contribution of RAR-VDR 
in vitamin D signa ling afte r 9-r-RA. and 1 ,2s(OH )2D} co-treatment 
cannot be excluded. T his is unlikely to be of m ajo r signifi cance in 
human ski.n , however, beca use in epidermal nuclear extract prep-
arations, we do not detect endogenous RAR-VDR heterodimers 
binding to VDREs (Li c/ (/ / , 1997). Furthermore, in o Ur ;11 I1;lro 
transfection system and in C57BL/6 adul t Inice ill 11;110 , the use of 
RXR-specifi c ligand SR 11237 provided results th at were compa-
rable w ith that of 9-c-RA, synergistically ellhan cing 24- 0Hase 
mRNA induction by 1,25(OH)2D, (Li cl (//, 1997) . The lack of 
adequate toxicology data to assure safe use in humans prevented us 
from applying this synthetic compound to o ur normal volunteers 
(hence its app lication to mice). 
Si milar to 9-c-RA , I-RA synerg istica Ll y enhan ced 24-0Hase 
mRNA i.nduction with a low dose (0.002'10,) of 1,2s(OH)2DJ ' 
Compared to 1,2s(OH)2D} treatm ent alo ne, addition of I-RA 
increased the transcrip t level by 50%, and 9-c-RA did so by 76% 
(I' = 0.74 liS 50'1., in crease). The comparab le magnitude of modest 
synergism caused by the two RA isomers with 1 ,25(OHhD, is not 
inconsisten t with R XR-VDR being the major heterodimer com-
plex in vitamin D signaling in human skin ;11 11 ; 110 . We have recently 
reported that the sa me 0.1 "/t, solution of I-RA applied to human skin 
for 48 h yie lded approximate ly 7 nM 9-c-RA in the viable epidemus 
(Duell el (/ /, 1996). Dissociation constant (K,,) va lues reported for 
9-c-RA binding to RXRs have ranged fro m 11 to 18 nM (Heyman 
el (/ /, 1. 992; Levin cl (//, 1992; Allenby c ( ai, 1993). T he Kd 
dete rmination made with endogenous retino id receptors (RXR and 
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RAR combined) in nuclear extracts from human epidemns, in 
winch the level ofRXR protein is 5-fold greater than that ofRAR 
protein, was 1.2 nM (Fisher et ai, 1994) . Therefore, the 7nM 
9-c-RA that form s after 0 .1 % t-RA may be sufricient to activate skin 
RXRs. Indeed , although 0.1 % 9-c-RA treatment results in 260 11M 
9-c-RA in stratum corneum-free epidermis (Duell e/ ai, 1996), no 
significant difference in synergism with l,25(OHhD3 was detected 
between 9-c-RA and I-RA (Figs 2, 3) . 
Although both t-RA and 9-c-RA augmented vitamin 0 signaling, 
1,25(OH)20 3' at concentrations used in our study, did not increase 
or decrease the abil.ity of t-RA or 9-c-RA to stimulate relevant 
target genes. When the blots were stripped of 24-0Hase probes 
and reprobed with CRABP-U probes, we found, consistent with 
previous observations (Kang ct ai , 1995; Elder ct ai , 1996), that both 
t-RA and 9-c-RA markedly induced CRABP-II mRNA levels. 
Compared with a single treatment of /-RA or 9-c-RA, co-admin-
istration of each RA isomer with 1,25(OHhD3 did not influence 
the level of CRABP-II gene transcripts (data not shown). 
In human skin ;11 1);110, neither 9-c-RA nor t-RA alone induced 
24-0Hase mR.NA expression . Similar results were obtained from 
cultured human keratinocytes and mouse skin ;11 1) ;1)0 (Li e/ ai, 
1997). By contrast, in mouse kidney systemic administration of 
both natural and synthetic RXR ligands enhanced the expression of 
the 24-0Hase gene without the presence of vitamin 0 3 (Allegretto 
et ai, 1995). This apparent tissue-specific gene regulation indicates 
that, in addition to the receptors and their cognate I.igands, other 
factors are involved in the process . The importance of relative ratios 
ofVDR and RKR in de termining the degree of ligand responsive-
ness (Lemon and Frceman, 1996) and the identity of the RXR 
isoform in influencing VDR hetcrodimer transactivation of the 
24-0Hase genc by l,25(OHh03 and 9-c-RA (Kephart et ai, 1996) 
were recently demonstrated . It is also possible that as described for 
es trogen and thyroid hormone receptors (Chen and Evans, 1995 ; 
H6r1ein c/ ai, 1995) , co-activator and/or co-repressor proteins may 
be modulating VDR imd RXl~ activities. There fore, tissue-re-
stricted expression of the receptors/rcceptor isoforms and/ or co-
activators/ co-repressors may be responsible in part, for the differ-
ential response to ligands observed in skin and kidney. 
Ketoconazole is a broad-spectrum P-450 inhibitor that has been 
used clinically in a variety of conditions ranging from fungal 
infections, seborrheic dermatitis, and psoriasis to prostatic carci-
noma (Farr e/ ai, 1985; Green et ai, 1987; Mah ler e/ ai, 1993; 
Degreefand OeOoncker, 1994). TopicaLly, ketoconazole has been 
safely used as a 2'Yo cream and shampoo formulations. W e found 1 % 
ketoco nazole to be cffective in syncrgistically increasing the 24-
OHase mR.NA level caused by a low dose of 1,25(OHhD3· The 
marked inhibition of 1,25(OH)20 :I-induced human epidermal 24-
OHase activity by kctoconazole ex 1/;110 (Fig 5) implies that the 
synergism ;11 1/;1)0 was achieved by impeding the inactivation of 
1 ,25(OHh03 by topical ketoconazo le. By itself, however, applica-
tion of ketoconazole did not induce 24-0l-Iase mRNA expression. 
T his is probably bcca use, under ;11 11;1/0 conditions, an effective 
inhibition of 24-0Hase activity by topical ketoconazole does not 
increase endogenous 1 ,25(OH)~03 to a level sufficient to indu ce 
24-0Hase mRNA. 
Our data indica te that vitamin 0 signaling in human skin ;11 IIiI/O 
can be signifi cantly incrcascd by two different mechanisms: RXR 
li gands and 24-0Hase inh.ibitors. Although not studi ed herein , 
RXR l.igands may also increase vitamin 0 signaling by synthetic 
compounds, such as calcipotriene, which can bind and transactivatc 
target genes via VOl~. 13ccause the synergistic e ffects observed with 
9-c-RA and ketoconazo le are m cdiated by distinct pathways, we 
speculate that a combination of both might nlrther enhance the 
bioactivity of l,25(Ol-I)20 3. This type of enhanccment in clinically 
relevant situations, however, still necds to be invcstigated . If found 
to be practical and effcctive, combination topical therapy with 
RKR agonist and/or 24- 0Hase inh.ibitor wou ld aUow use of less 
1,25 (OH) 20 3' than would be necessary wh en using 1 ,25(OH)~03 
as a single agent, to deliver a desired biologic/therapeutic response 
to human skin . In principle, a redu ction in tlle amount of applied 
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1,25(OH)2D3 required to produce a pharmacologic effect would 
minimize potential risk of hypercalcemia. 
Hfe thallk 511zall R chbille for her expe/tise ;11 applyillg the COli/pOll lids alld 
keratoll/illg of the treated areas, Ted A. Hall/i1toll for statisliw l allalysis, Lallra Vall 
Goor for th e i/lllsiratiolls, mid TOil, Kllczajda fo r secretarial ass is/alice. Hfe also 
Ihallk Li Qill fo r peifom,illg 1I0l1hem blot atl(llysis alld Dr. M .R . Hallssler fo r 
prollidillg /lIl1l1all 24-0Hase eDNA. 5.K. is a recipiellt of Ihe D e,ma/ology 
FOlllldatioll , Gla ;,"o Derll/atology C lill ;cal Career D ellelop," e"t A ward. This work 
was sllPported ill pat1 by the Babcock Elldo,vlI/elll allli the ) 0 /111.1011 alld )0/111.10 11 
Co'poralioll. 
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